Profile data is unavailable for this security.
About the company
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
- Revenue in USD (TTM)258.72m
- Net income in USD13.08m
- Incorporated1989
- Employees357.00
- LocationVericel Corp64 Sidney StCAMBRIDGE 02139United StatesUSA
- Phone+1 (734) 930-5555
- Fax+1 (734) 665-0485
- Websitehttps://vcel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 757.07m | 58.44m | 1.45bn | 357.00 | 28.56 | 5.27 | 5.09 | 1.91 | 1.60 | 1.60 | 19.94 | 8.70 | 0.467 | 8.51 | 3.27 | 2,120,636.00 | 3.60 | 4.11 | 5.02 | 6.64 | 57.22 | 55.50 | 7.72 | 8.48 | 1.27 | 2.23 | 0.7462 | 0.00 | 11.41 | 16.31 | 43.68 | -- | -23.82 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.62bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 379.59m | -29.23m | 1.63bn | 493.00 | -- | -- | -- | 4.30 | -0.5866 | -0.5866 | 7.49 | -- | 0.3471 | 0.5336 | 5.44 | 769,959.40 | -2.67 | -17.90 | -3.34 | -23.26 | 99.29 | -- | -7.70 | -53.74 | 5.97 | -- | 0.4975 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Innoviva Inc | 388.52m | 127.34m | 1.70bn | 127.00 | 17.59 | 1.68 | 10.14 | 4.37 | 1.29 | 1.29 | 4.57 | 13.51 | 0.292 | 1.98 | 4.21 | 3,059,221.00 | 9.57 | 20.06 | 10.66 | 22.10 | 81.50 | -- | 32.78 | 62.81 | 13.33 | 18.15 | 0.2031 | -- | 15.54 | 6.57 | -86.98 | -31.69 | 223.78 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.74bn | 897.00 | 47.44 | 3.44 | 13.33 | 2.10 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Precigen Inc | 6.31m | -425.87m | 1.74bn | 143.00 | -- | 41.66 | -- | 276.49 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.77bn | 382.00 | -- | 37.57 | 129.10 | 7.06 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| Vericel Corp | 258.72m | 13.08m | 1.82bn | 357.00 | 192.09 | 5.65 | 78.45 | 7.03 | 0.1872 | 0.1872 | 4.86 | 6.37 | 0.6133 | 4.00 | 4.75 | 724,697.50 | 3.10 | -1.03 | 3.46 | -1.18 | 73.81 | 69.10 | 5.06 | -1.61 | 4.47 | -- | 0.002 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| Sarepta Therapeutics Inc | 2.41bn | -271.51m | 1.86bn | 1.37k | -- | 1.41 | -- | 0.7723 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Aurinia Pharmaceuticals Inc | 265.81m | 77.84m | 1.88bn | 300.00 | 25.37 | 5.13 | 19.28 | 7.06 | 0.561 | 0.561 | 1.88 | 2.77 | 0.4937 | 0.7046 | 7.91 | -- | 14.46 | -18.84 | 16.88 | -20.97 | 88.93 | -- | 29.28 | -72.47 | 5.17 | -- | 0.1645 | -- | 33.97 | 274.78 | 107.37 | -- | 22.71 | -- |
| Organon & Co | 6.30bn | 501.00m | 1.92bn | 10.00k | 3.84 | 2.12 | 2.28 | 0.3049 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.93bn | 325.00 | -- | 2.93 | -- | 37.21 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Ultragenyx Pharmaceutical Inc | 672.72m | -575.44m | 1.98bn | 1.29k | -- | -- | -- | 2.94 | -5.84 | -5.84 | 6.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 83.85 | 88.44 | -85.54 | -122.25 | -- | -12.60 | -- | -- | 20.13 | 19.95 | -1.02 | -- | -- | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 2.00bn | 8.38k | -- | 0.45 | 6.61 | 0.4673 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.07bn | 246.00 | 11.34 | 2.48 | 9.90 | 2.51 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
Data as of Feb 13 2026. Currency figures normalised to Vericel Corp's reporting currency: US Dollar USD
52.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 7.11m | 14.06% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.17m | 6.27% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.16m | 6.26% |
| Conestoga Capital Advisors LLCas of 31 Dec 2025 | 2.25m | 4.46% |
| William Blair Investment Management LLCas of 31 Dec 2025 | 2.22m | 4.39% |
| Brown Capital Management LLCas of 30 Sep 2025 | 1.95m | 3.86% |
| Geneva Capital Management LLCas of 31 Dec 2025 | 1.83m | 3.61% |
| Congress Asset Management Co. LLPas of 31 Dec 2025 | 1.66m | 3.29% |
| GW&K Investment Management LLCas of 31 Dec 2025 | 1.58m | 3.13% |
| BNP Paribas Asset Management USA, Inc.as of 31 Dec 2025 | 1.58m | 3.12% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
